February 14, 2025

To,
Dy. General Manager
Department of Corporate Services,
BSE Ltd.
Phiroze Jeejeebhoy Towers
Dalal Street, Fort, Mumbai – 400 001

Ref: Scrip Code: 532296

To,
The Manager – Listing,
The National Stock Exchange of India Ltd.,
Plot No. C/1, G Block
Bandra Kurla Complex,
Bandra (E), Mumbai – 400 051

Ref: Scrip Name: GLENMARK

Re: *Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015*

Dear Sir,

Sub.: U.S. FDA inspection at the Company's Facility at Indore, Madhya Pradesh, India

Pursuant to Regulation 30 of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015, this is to inform you that the United States Food & Drug Administration (USFDA) conducted a GMP inspection at the Company's manufacturing facility situated in Indore, Madhya Pradesh from 03 February 2025 to 14 February 2025.

At the end of the inspection, the Company was issued a Form 483 with five (5) observations. There was no observation related to data integrity reported. The Company will work in close collaboration with the agency to address the observations and will respond to the USFDA within the stipulated timeline.
Please take the above information on record.

Thanking you,

Yours faithfully,
For Glenmark Pharmaceuticals Limited

HARISH VINAYAK KUBER
Digitally signed by HARISH VINAYAK KUBER
Date: 2025.02.14 19:28:05 +05'30'

Harish Kuber
Company Secretary & Compliance Officer